What is Condor?
Condor operates at the intersection of fintech and life sciences, offering a robust software suite designed to manage the intricate financial demands of clinical research. The platform serves as a centralized hub for biopharmaceutical companies to track R&D expenditures, optimize vendor operations, and ensure budgetary compliance across multi-site clinical trials. By replacing legacy manual processes with automated, data-driven intelligence, Condor enables organizations to achieve greater operational efficiency and financial transparency. Its market position is defined by its ability to bridge the gap between complex scientific research requirements and rigorous corporate financial governance, making it an essential tool for modern drug development pipelines.
How much funding has Condor raised?
Condor has raised a total of $24M across 1 funding round:
Series A
$24M
Series A (2026): $24M with participation from Felicis Ventures, Snr, Bramalea Partners, 645 Ventures, and Insight Partners
Key Investors in Condor
Felicis Ventures
A Menlo Park-based venture capital firm that raises multistage funds to invest in early and growth-stage technology companies across sectors such as SaaS, AI, and fintech.
Snr
An early-stage venture capital firm focused on identifying and investing in promising startups while providing valuable support and resources to help portfolio companies navigate growth challenges.
Bramalea Partners
A Boston-based firm specializing in partnering with exceptional expansion-stage technology companies to assist management teams in achieving sustainable and capital-efficient growth.
What's next for Condor?
With this latest infusion of capital, Condor is expected to prioritize the scaling of its enterprise software capabilities and the expansion of its market reach. The strategic focus will likely involve enhancing the platform's predictive analytics engine to provide deeper insights into clinical trial cost structures, thereby enabling more agile resource allocation for its clients. Furthermore, the company is poised to strengthen its operational support infrastructure to accommodate a growing roster of global biopharmaceutical partners. As the life sciences industry continues to face pressure to reduce time-to-market for new therapies, Condor's role in optimizing the financial backbone of these research initiatives will be critical to its long-term growth trajectory and competitive differentiation in the SaaS landscape.
See full Condor company page
